Published online Mar 16, 2023. doi: 10.12998/wjcc.v11.i8.1730
Peer-review started: January 4, 2023
First decision: January 14, 2023
Revised: January 14, 2023
Accepted: February 21, 2023
Article in press: February 21, 2023
Published online: March 16, 2023
Processing time: 62 Days and 2.3 Hours
Inflammatory bowel disease (IBD) is often diagnosed during the peak reprodu
Core Tip: Anti-tumor necrosis factor monotherapy is safe during pregnancy in women with Inflammatory bowel disease (IBD). However, their use in combination with thiopurines may be associated increased risk of neonatal prematurity and infection, although these data are conflicting. According to meta-analyses, vedolizumab and ustekinumab may be associated with early pregnancy loss; however, these data might be biased by IBD activity or small sample sizes. Recent prospective studies have demonstrated these biologics are generally safe during pregnancy. Janus kinase inhibitors are contraindicated during pregnancy as animal studies have demonstrated harmful effects. Calcineurin inhibitors may be considered for pregnant women with IBD who develop clinical relapse.